SP_VIRAL HEPATITIS AND IMMUNE CHECKPOINT INHIBITORS: HOW ARE CANCER PATIENTS MANAGED?
A survey on the management of patients with solid tumor and ongoing or recovered hepatitis B or/and C virus [HBV, HCV] infection treated with immune checkpoint inhibitors [ICI, i.e anti PD-1, anti PD-L1, anti CTLA-4]
Sign in to Google to save your progress. Learn more
1 - Do you think that a better definition of how to manage chronic infection by HBV and HCV in cancer patients who receive an ICI could be useful? *
2 - Are you usually afraid of treating with ICI patients with solid tumor and chronic HBV or/and HCV infection? *
(chronic HBV infection = positive HBsAg or detectable HBV-DNA, negative anti-HBs; chronic HCV infection = detectable HCV-RNA)
3 - If the previous answer was yes, what does make you afraid?
Clear selection
4 - Do you usually exclude patients with recovered HBV infection and/or previous HCV infection from ICI treatment? *
(recovered HBV infection = positive anti-HBc, positive anti-HBs; previous HCV infection = positive anti-HCV, undetectable HCV-RNA)
5 - How many patients with advanced stage solid tumor have been treated in any line in your Hospital with ICI, outside of clinical trials and irrespectively of HBV/HCV status, between the introduction of these drugs in clinical practice and April 30 2019? *
(including patients in expanded access programs - EAP)
6 - Do you usually test for HBV and HCV before starting an ICI? *
7 - If the previous answer was yes, which tests do you routinely perform?
Clear selection
8 - Do you usually refer cancer patients with ongoing HBV or/and HCV infection, candidate to receive an ICI, to the infectious disease specialist or hepatologist? *
9 - Which percentage of patients with solid tumor and chronic HBV infection, with indication to receive an ICI in clinical practice or within EAP until April 30 2019, has then actually been treated with immunotherapy in your Hospital? *
(chronic HBV infection = positive HBsAg or detectable HBV-DNA, negative anti-HBs)
10 - Which percentage of patients with solid tumor and chronic HCV infection, with indication to receive an ICI in clinical practice or within EAP until April 30 2019, has then actually been treated with immunotherapy in your Hospital? *
(chronic HCV infection = detectable HCV-RNA)
11 - Which percentage of patients with solid tumor and recovered HBV infection, with indication to receive an ICI in clinical practice or within EAP until April 30 2019, has then actually been treated with immunotherapy in your Hospital? *
(recovered HBV infection = positive anti-HBc, positive anti-HBs)
12 - Which percentage of patients with solid tumor and previous HCV infection, with indication to receive an ICI in clinical practice or within EAP until April 30 2019, has then actually been treated with immunotherapy in your Hospital? *
(previous HCV infection = positive anti-HCV, undetectable HCV-RNA)
13 - Please indicate the percentages of patients, treated in your Hospital with ICI in clinical practice or within EAP, according to the following cancer types: *
0% - 10%
11% - 20%
21% - 40%
41% - 60%
61% 80%
81% - 100%
Melanoma
Lung Cancer
Renal cell carcinoma
Urothelial carcinoma
Head and neck cancer
Hepatocellular carcinoma
Others
14 - How do you usually manage cancer patients with chronic HBV or/and HCV infection when treating with ICI? *
(chronic HBV infection = positive HBsAg or detectable HBV-DNA, negative anti-HBs; chronic HCV infection = detectable HCV-RNA)
Submit
Clear form
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy
Google Forms